文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

调强放射治疗在局部晚期肺癌中的剂量学优势

Dosimetric advantages of intensity modulated radiation therapy in locally advanced lung cancer.

作者信息

Boyle John, Ackerson Brad, Gu Lin, Kelsey Chris R

机构信息

Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.

Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina.

出版信息

Adv Radiat Oncol. 2017 Jan 3;2(1):6-11. doi: 10.1016/j.adro.2016.12.006. eCollection 2017 Jan-Mar.


DOI:10.1016/j.adro.2016.12.006
PMID:28740910
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5514227/
Abstract

PURPOSE: Radiation therapy plays an essential role in the treatment of locally advanced lung cancer, but it inevitably leads to incidental and unnecessary dose to critical organs, including the lung, heart, and esophagus. Numerous radiation dose-volumetric parameters have been associated with increased risk of morbidity and mortality. The purpose of the present study is to quantify differences in normal tissue radiation exposure with intensity modulated radiation therapy (IMRT) compared with 3-dimensional conformal radiation therapy (3D-CRT). METHODS AND MATERIALS: Twenty-four consecutive patients with locally advanced lung cancer undergoing definitive IMRT were enrolled on a phase 1 protocol. For each patient, an optimized 3D-CRT plan was also designed. Plans were normalized in terms of planning target coverage with a standard dose of 60 Gy in 2-Gy fractions with a subset of patients also receiving elective nodal irradiation to a dose of 44 Gy in 2-Gy fractions. Normal tissue dosimetric comparisons were made for the lung, heart, and esophagus. RESULTS: IMRT decreased incidental dose to the lungs, heart, and esophagus. For lung, both V20 Gy (21.5% vs 26.5%, < .01) and mean lung dose (11.9 Gy vs 14.9 Gy, < .01) were improved with IMRT without a corresponding increase in V5 Gy ( = .76). For heart, there was improvement in V5 (28.9% vs 33.7%, < .01) but no difference in V30 Gy (9.8% vs 15.9%.  = .10). For esophagus, all dosimetric endpoints were improved (V20 Gy, V45 Gy, V60 Gy, mean dose). For example, V60 was 6.5% with IMRT compared with 21% with 3D-CRT ( < .01). CONCLUSIONS: IMRT significantly decreased unnecessary dose to critical organs with equivalent coverage of planning target volumes. IMRT may therefore improve the tolerability of therapy.

摘要

目的:放射治疗在局部晚期肺癌的治疗中起着至关重要的作用,但不可避免地会对包括肺、心脏和食管在内的关键器官造成附带且不必要的剂量。众多辐射剂量体积参数已与发病率和死亡率的增加风险相关联。本研究的目的是量化调强放射治疗(IMRT)与三维适形放射治疗(3D-CRT)相比在正常组织辐射暴露方面的差异。 方法与材料:连续24例接受根治性IMRT的局部晚期肺癌患者纳入1期方案。对于每位患者,还设计了优化的3D-CRT计划。计划根据计划靶区覆盖情况进行归一化,标准剂量为60 Gy,分2 Gy分次给予,部分患者还接受选择性淋巴结照射,剂量为44 Gy,分2 Gy分次给予。对肺、心脏和食管进行正常组织剂量学比较。 结果:IMRT降低了对肺、心脏和食管的附带剂量。对于肺,IMRT使V20 Gy(21.5%对26.5%,P<0.01)和平均肺剂量(11.9 Gy对14.9 Gy,P<0.01)均得到改善,而V5 Gy无相应增加(P = 0.76)。对于心脏,V5得到改善(28.9%对33.7%,P<0.01),但V30 Gy无差异(9.8%对15.9%,P = 0.10)。对于食管,所有剂量学终点均得到改善(V20 Gy、V45 Gy、V60 Gy、平均剂量)。例如,IMRT时V60为6.5%,而3D-CRT时为21%(P<0.01)。 结论:IMRT在计划靶区体积等效覆盖的情况下,显著降低了对关键器官的不必要剂量。因此,IMRT可能会提高治疗的耐受性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad18/5514227/d145da2d4e23/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad18/5514227/e2087090374e/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad18/5514227/38e6be79a240/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad18/5514227/d145da2d4e23/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad18/5514227/e2087090374e/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad18/5514227/38e6be79a240/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad18/5514227/d145da2d4e23/gr3.jpg

相似文献

[1]
Dosimetric advantages of intensity modulated radiation therapy in locally advanced lung cancer.

Adv Radiat Oncol. 2017-1-3

[2]
Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation.

Int J Radiat Oncol Biol Phys. 2003-11-1

[3]
Intensity-modulated radiotherapy in nasopharyngeal carcinoma: dosimetric advantage over conventional plans and feasibility of dose escalation.

Int J Radiat Oncol Biol Phys. 2003-5-1

[4]
A dosimetric evaluation of dose escalation for the radical treatment of locally advanced vulvar cancer by intensity-modulated radiation therapy.

Med Dosim. 2012

[5]
Volumetric modulation arc radiotherapy with flattening filter-free beams compared with static gantry IMRT and 3D conformal radiotherapy for advanced esophageal cancer: a feasibility study.

Int J Radiat Oncol Biol Phys. 2012-3-2

[6]
Dosimetric comparison of axilla and groin radiotherapy techniques for high-risk and locally advanced skin cancer.

Radiat Oncol J. 2016-6

[7]
IMRT and 3D conformal radiotherapy with or without elective nodal irradiation in locally advanced NSCLC: A direct comparison of PET-based treatment planning.

Strahlenther Onkol. 2016-2

[8]
Dosimetric comparison of IMRT versus 3DCRT for post-mastectomy chest wall irradiation.

Radiat Oncol J. 2018-3

[9]
[Dosimetric analysis of volumetric modulated arc therapy and intensity modulated radiotherapy for patients undergone breast-conserving operation].

Beijing Da Xue Xue Bao Yi Xue Ban. 2018-2-18

[10]
[Dose distributions of proton beam therapy for hepatocellular carcinoma: a comparative study of treatment planning with 3D-conformal radiation therapy or intensity-modulated radiation therapy].

Zhonghua Yi Xue Za Zhi. 2009-12-8

引用本文的文献

[1]
The Era of Precision Medicine: Advancing Treatment Paradigms for Small Cell Lung Cancer.

Cancers (Basel). 2025-5-31

[2]
Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions.

J Clin Med. 2024-7-18

[3]
Dosimetric comparison of five different radiotherapy treatment planning approaches for locally advanced non-small cell lung cancer with sequential plan changes.

Thorac Cancer. 2023-12

[4]
Learning curve of lung dose optimization in intensity-modulated radiotherapy for locally advanced non-small cell lung cancer.

Thorac Cancer. 2023-9

[5]
Cardiotoxicity of Anti-Cancer Radiation Therapy: a Focus on Heart Failure.

Curr Heart Fail Rep. 2023-2

[6]
Simple method for evaluating achievement degree of lung dose optimization in individual patients with locally advanced non-small cell lung cancer treated with intensity modulated radiotherapy.

Thorac Cancer. 2022-10

[7]
Radiation-induced coronary artery disease: a difficult clinical conundrum.

Clin Med (Lond). 2022-5

[8]
Optimal management of recurrent and metastatic upper tract urothelial carcinoma: Implications of intensity modulated radiation therapy.

Radiat Oncol. 2022-3-9

[9]
Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer.

Radiat Oncol. 2022-1-15

[10]
Development of a novel detection method for changes in lung conditions during radiotherapy using a temporal subtraction technique.

Phys Eng Sci Med. 2021-12

本文引用的文献

[1]
Limiting the risk of cardiac toxicity with esophageal-sparing intensity modulated radiotherapy for locally advanced lung cancers.

J Thorac Dis. 2016-5

[2]
Is IMRT Superior or Inferior to 3DCRT in Radiotherapy for NSCLC? A Meta-Analysis.

PLoS One. 2016-4-21

[3]
Phase 1 Dose Escalation Study of Accelerated Radiation Therapy With Concurrent Chemotherapy for Locally Advanced Lung Cancer.

Int J Radiat Oncol Biol Phys. 2015-9-15

[4]
Non-Small Cell Lung Cancer, Version 6.2015.

J Natl Compr Canc Netw. 2015-5

[5]
Effect of Radiation Therapy Techniques on Outcome in N3-positive IIIB Non-small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy.

Cancer Res Treat. 2016-1

[6]
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.

Lancet Oncol. 2015-2

[7]
Comparative effectiveness of intensity-modulated versus 3D conformal radiation therapy among medicare patients with stage III lung cancer.

J Thorac Oncol. 2014-12

[8]
A population-based study of primary chemoradiotherapy in clinical stage III non-small cell lung cancer: intensity-modulated radiotherapy versus 3D conformal radiotherapy.

Anticancer Res. 2014-9

[9]
A population-based comparative effectiveness study of radiation therapy techniques in stage III non-small cell lung cancer.

Int J Radiat Oncol Biol Phys. 2014-2-1

[10]
Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual patient data meta-analysis.

Int J Radiat Oncol Biol Phys. 2013-9-10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索